Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2008, Article ID 825093, 4 pages
http://dx.doi.org/10.1155/2008/825093
Case Report

Targeting mTOR in HIV-Negative Classic Kaposi's Sarcoma

1Unit of Bone and Soft Tissue Oncology, Division of Oncology, Tel-Aviv Sourasky Medical Center, 6 Weitzman Street, Tel-Aviv 64239, Israel
2Sackler School of Medicine, Tel-Aviv University, Tel-Aviv 64239, Israel
3Department of Cell and Developmental Biology, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel

Received 3 November 2007; Accepted 26 February 2008

Academic Editor: Jose Casanova

Copyright © 2008 Ofer Merimsky et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. B. Brash and A. E. Bale, “Molecular biology of skin cancer,” in Cancer Principles and Practice of Oncology, V. T. DeVita, Jr., S. Hellman, and S. Rosenberg, Eds., p. 1971, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 2000. View at Google Scholar
  2. P. McCaffrey, “Sirolimus does double duty after organ transplantation,” The Lancet Oncology, vol. 6, no. 5, 261 pages, 2005. View at Publisher · View at Google Scholar
  3. N. Mohsin, M. Budruddin, A. Pakkyara et al., “Complete regression of visceral Kaposi's sarcoma after conversion to sirolimus,” Experimental and Clinical Transplantation, vol. 3, no. 2, 366 pages, 2005. View at Google Scholar
  4. M. S. Vasanawala, Y. Wang, A. Quon, and S. S. Gambhir, “F-18 fluorodeoxyglucose PET/CT as an imaging tool for staging and restaging cutaneous angiosarcoma of the scalp,” Clinical Nuclear Medicine, vol. 31, no. 9, 534 pages, 2006. View at Publisher · View at Google Scholar · View at PubMed
  5. P. Dupont and A. N. Warrens, “The evolving role of sirolimus in renal transplantation,” QJM, vol. 96, no. 6, 401 pages, 2003. View at Publisher · View at Google Scholar
  6. C. T. Keith and S. L. Schreiber, “PIK-related kinases: DNA repair, recombination, and cell cycle checkpoints,” Science, vol. 270, no. 5233, 50 pages, 1995. View at Publisher · View at Google Scholar
  7. H. B. J. Jefferies, S. Fumagalli, P. B. Dennis, C. Reinhard, R. B. Pearson, and G. Thomas, “Rapamycin suppresses 5TOP mRNA translation through inhibition of p70s6k,” The EMBO Journal, vol. 16, no. 12, 3693 pages, 1997. View at Publisher · View at Google Scholar · View at PubMed
  8. N. Sonenberg and A.-C. Gingras, “The mRNA 5 cap-binding protein elF4E and control of cell growth,” Current Opinion in Cell Biology, vol. 10, no. 2, 268 pages, 1998. View at Publisher · View at Google Scholar
  9. D. C. Fingar, C. J. Richardson, A. R. Tee, L. Cheatham, C. Tsou, and J. Blenis, “mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E,” Molecular and Cellular Biology, vol. 24, no. 1, 200 pages, 2004. View at Publisher · View at Google Scholar
  10. S. Huang, M. A. Bjornsti, and P. J. Houghton, “Rapamycins: mechanism of action and cellular resistance,” Cancer Biology & Therapy, vol. 2, no. 3, 222 pages, 2003. View at Google Scholar
  11. J. Chen, “Novel regulatory mechanisms of mTOR signaling,” Current Topics in Microbiology and Immunology, vol. 279, 245 pages, 2003. View at Google Scholar
  12. J. Chen, X.-F. Zheng, E. J. Brown, and S. L. Schreiber, “Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 11, 4947 pages, 1995. View at Publisher · View at Google Scholar
  13. M. M. Mita, A. Mita, and E. K. Rowinsky, “Mammalian target of rapamycin: a new molecular target for breast cancer,” Clinical Breast Cancer, vol. 4, no. 2, 126 pages, 2003. View at Google Scholar
  14. M. Guba, P. von Breitenbuch, M. Steinbauer et al., “Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor,” Nature Medicine, vol. 8, no. 2, 128 pages, 2002. View at Publisher · View at Google Scholar · View at PubMed
  15. J. E. Dancey, “Clinical development of mammalian target of rapamycin inhibitors,” Hematology/Oncology Clinics of North America, vol. 16, no. 5, 1101 pages, 2002. View at Publisher · View at Google Scholar
  16. Y. Shi, A. Frankel, L. G. Radvanyi, L. Z. Penn, R. G. Miller, and G. B. Mills, “Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro,” Cancer Research, vol. 55, no. 9, 1982 pages, 1995. View at Google Scholar
  17. J. S. Eshleman, B. L. Carlson, A. C. Mladek, B. D. Kastner, K. L. Shide, and J. N. Sarkaria, “Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy,” Cancer Research, vol. 62, no. 24, 7291 pages, 2002. View at Google Scholar
  18. S. Huang and P. J. Houghton, “Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic,” Current Opinion in Investigational Drugs, vol. 3, no. 2, 295 pages, 2002. View at Google Scholar
  19. S. Montaner, “Akt/TSC/mTOR activation by the KSHV G protein-coupled receptor: emerging insights into the molecular oncogenesis and treatment of Kaposi's sarcoma,” Cell Cycle, vol. 6, no. 4, 438 pages, 2007. View at Google Scholar
  20. Y. Chang, E. Cesarman, M. S. Pessin et al., “Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma,” Science, vol. 266, no. 5192, 1865 pages, 1994. View at Publisher · View at Google Scholar
  21. S. Montaner, A. Sodhi, A. Molinolo et al., “Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes,” Cancer Cell, vol. 3, no. 1, 23 pages, 2003. View at Publisher · View at Google Scholar
  22. L. A. Dourmishev, A. L. Dourmishev, D. Palmeri, R. A. Schwartz, and D. M. Lukac, “Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) epidemiology and pathogenesis,” Microbiology and Molecular Biology Reviews, vol. 67, no. 2, 175 pages, 2003. View at Publisher · View at Google Scholar
  23. A. Sodhi, S. Montaner, V. Patel et al., “Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 14, 4821 pages, 2004. View at Publisher · View at Google Scholar · View at PubMed
  24. B. D. Manning and L. C. Cantley, “United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling,” Biochemical Society Transactions, vol. 31, no. 3, 573 pages, 2003. View at Publisher · View at Google Scholar
  25. C. J. Richardson, S. S. Schalm, and J. Blenis, “PI3-kinase and TOR: PIKTORing cell growth,” Seminars in Cell & Developmental Biology, vol. 15, no. 2, 147 pages, 2004. View at Publisher · View at Google Scholar